

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
14 December 2023 (14.12.2023)



(10) International Publication Number
WO 2023/237511 A1

(51) International Patent Classification:

A61K 31/192 (2006.01) A61P 9/12 (2006.01)
A61P 9/04 (2006.01)

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2023/065045

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

(22) International Filing Date:

06 June 2023 (06.06.2023)

Published:

— with international search report (Art. 21(3))
— in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/365,971 07 June 2022 (07.06.2022) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; 151 85
Södertälje (SE).

(72) Inventors: **GABRIELSEN, Anders**; AstraZeneca AB,
SE-151 85 Södertälje (SE). **GEORGE JR., Richard
Thomas**; AstraZeneca Pharmaceuticals LP, 1800 Concord
Pike, Wilmington, Delaware 19850-5437 (US). **CONNOL-
LY, Kathleen Marie**; AstraZeneca UK Limited, 1 Francis
Crick Avenue, Cambridge Biomedical Campus, Cam-
bridge Cambridgeshire CB2 0AA (GB). **OMAR, Sami
Ali Abdel Hafees**; AstraZeneca UK Limited, 1 Francis
Crick Avenue, Cambridge Biomedical Campus, Cambridge
Cambridgeshire CB2 0AA (GB). **UFNAL, Marcin**; As-
traZeneca Pharma Poland SP. Z O.O. Postępu 14, 02-676
Warszawa (PL).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPER-
TY**; Eastbrook House, Shaftesbury Road, CAMBRIDGE
Cambridgeshire CB2 8BF (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: RXFP1 MODULATORS FOR TREATING RESISTANT HYPERTENSION OR HEART FAILURE WITH PULMONARY HYPERTENSION

(57) Abstract: The specification generally relates to uses of RXFP1 modulators, in particular methods of treating resistant hypertension and heart failure with pulmonary hypertension.

WO 2023/237511 A1